EssilorLuxottica Societe anonyme

EssilorLuxottica Societe anonyme Earnings Recaps

EL.PA Health Care 1 recap
Q2 2026 Jul 30, 2026

EssilorLuxottica reported stable H1 2026 results with solid revenue and profit growth, but the stock was largely unchanged (-0.2%) as investors balanced the company’s ongoing transformation and innovation against limited near-term financial acceleration.

Key takeaways
  • Revenue grew 9.7% at constant currency, driven by frames, lenses, and significant growth in clinical and wearable segments.
  • Adjusted operating profit increased 15%, reflecting operating leverage despite ongoing investments in R&D, AI, and medical capabilities.
  • Cash generation remained strong, exceeding €1 billion in the first half.
  • Strategic initiatives include the launch of LensCrafters’ integrated eye health surgery center and a partnership with Applied Materials to develop next-generation AI and AR eyewear technologies.
  • Wearables category expanded with new Ray-Ban Meta Optical models and growing profitability, though broader market adoption remains an investment focus.